Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

被引:0
|
作者
Wessel, Didrik [1 ,2 ]
Pogrebnyakov, Nicolai [1 ]
机构
[1] Copenhagen Business Sch, Frederiksberg, Denmark
[2] Norrebrogade 18A 3TH, DK-2200 Copenhagen, Denmark
关键词
PHARMACOVIGILANCE; TWITTER; TOOL;
D O I
10.1007/s40264-024-01409-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionWhile pharmaceutical companies aim to leverage real-world data (RWD) to bridge the gap between clinical drug development and real-world patient outcomes, extant research has mainly focused on the use of social media in a post-approval safety-surveillance setting. Recent regulatory and technological developments indicate that social media may serve as a rich source to expand the evidence base to pre-approval and drug development activities. However, use cases related to drug development have been largely omitted, thereby missing some of the benefits of RWD. In addition, an applied end-to-end understanding of RWD rooted in both industry and regulations is lacking.ObjectiveWe aimed to investigate how social media can be used as a source of RWD to support regulatory decision making and drug development in the pharmaceutical industry. We aimed to specifically explore the data pipeline and examine how social-media derived RWD can align with regulatory guidance from the US Food and Drug Administration and industry needs.MethodsA machine learning pipeline was developed to extract patient insights related to anticoagulants from X (Twitter) data. These findings were then analysed from an industry perspective, and complemented by interviews with professionals from a pharmaceutical company.ResultsThe analysis reveals several use cases where RWD derived from social media can be beneficial, particularly in generating hypotheses around patient and therapeutic area needs. We also note certain limitations of social media data, particularly around inferring causality.ConclusionsSocial media display considerable potential as a source of RWD for guiding efforts in pharmaceutical drug development and pre-approval settings. Although further regulatory guidance on the use of social media for RWD is needed to encourage its use, regulatory and technological developments are suggested to warrant at least exploratory uses for drug development.
引用
收藏
页码:495 / 511
页数:17
相关论文
共 50 条
  • [1] Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making (vol 47, pg 495, 2024)
    Wessel, Didrik
    Pogrebnyakov, Nicolai
    [J]. DRUG SAFETY, 2024, 47 (08) : 827 - 827
  • [2] Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development
    Levenson, Mark
    He, Weili
    Chen, Li
    Dharmarajan, Sai
    Izem, Rima
    Meng, Zhaoling
    Pang, Herbert
    Rockhold, Frank
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 689 - 696
  • [3] The application of real-world evidence in drug regulatory decision-making
    Wicherski, Julia
    Haenisch, Britta
    [J]. BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2024, 67 (02) : 255 - 256
  • [4] Real-World Data Analytics Fit for Regulatory Decision-Making
    Schneeweiss, Sebastian
    Glynn, Robert J.
    [J]. AMERICAN JOURNAL OF LAW & MEDICINE, 2018, 44 (2-3) : 197 - 216
  • [5] Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making
    Yuan, Lily
    Rahman, Motiur
    Concato, John
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):
  • [6] Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea
    Lee, Hankil
    Ahn, Hyeon-Soo
    Kwon, Sol
    Kang, Hye-Young
    Han, Euna
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [7] Development of audit readiness considerations of real-world data for use in regulatory decision-making
    Atzinger, Christopher B.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 411 - 411
  • [8] Multidimensional Evidence Generation and FDA Regulatory Decision Making Defining and Using "Real-World" Data
    Jarow, Jonathan P.
    LaVange, Lisa
    Woodcock, Janet
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08): : 703 - 704
  • [9] Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
    Cave, Alison
    Kurz, Xavier
    Arlett, Peter
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) : 36 - 39
  • [10] SUITABILITY OF NORDIC REAL-WORLD DATA TO SUPPORT EU REGULATORY DECISION MAKING
    Geale, K.
    Grip, Toresson E.
    Ortsater, G.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S474 - S475